Hansoh Pharma

Hansoh Pharma, established in 2015, is a prominent pharmaceutical enterprise headquartered in Lianyungang, Jiangsu, China. The company specializes in innovation-driven drug development, maintaining a robust R&D pipeline focused on oncology, anti-infections, central nervous system (CNS) diseases, metabolic disorders, and autoimmune conditions. As a recognized national high-tech enterprise, Hansoh Pharma consistently ranks among the top 100 global pharmaceutical companies, leveraging advanced biopharmaceutical technologies to address critical unmet medical needs.

Operating with a workforce of 5,000-10,000 employees, the organization maintains two strategic locations to support its extensive clinical and commercial operations. The company’s commitment to technology innovation is reflected in its status as a national technology innovation exemplary enterprise. Meet Hansoh Pharma's team to understand the leadership driving these R&D initiatives and the organizational structure supporting their broad-spectrum treatment portfolio. The firm’s operational model emphasizes high-efficiency drug discovery and development processes, ensuring consistent delivery of therapeutic solutions to global markets.

Hansoh Pharma competes within a highly dynamic global landscape, facing competition from major industry players such as Jiangsu Hengrui Medicine Co., Ltd., Pfizer, and Novartis. With annual revenue reaching $1.7B, the company maintains a strong market position in the pharmaceutical sector. Its strategic focus on high-value therapeutic areas and continuous investment in R&D pipeline development underscores its long-term growth trajectory. By integrating advanced clinical research with scalable manufacturing capabilities, Hansoh Pharma continues to solidify its influence as a key contributor to the global healthcare ecosystem, consistently delivering innovative treatments that improve patient outcomes across diverse medical fields.